文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

台湾某三级教学医院皮肤软组织感染分离脓肿分枝杆菌复合群的耐药性分析

Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究对台湾某三级教学医院皮肤软组织感染患者分离的67株脓肿分枝杆菌复合群(MABC)进行菌种鉴定和11种抗分枝杆菌药物敏感性检测。结果显示多数菌株对环丙沙星、多西环素、亚胺培南、利奈唑胺、米诺环素、莫西沙星和复方磺胺甲噁唑耐药,对头孢西丁多呈中介或耐药,但多数对阿米卡星和替加环素敏感。结论提示阿米卡星、克拉霉素和替加环素对MMA及erm(41) C28型MAB有较好活性,而阿米卡星和替加环素(而非克拉霉素)对MBO及erm(41) T28型MAB有较好活性。

要点

  • 皮肤软组织感染分离的MABC多数对氟喹诺酮类、四环素类、亚胺培南、利奈唑胺和复方磺胺甲噁唑耐药。
  • 多数MABC对阿米卡星和替加环素敏感,对头孢西丁多呈中介或耐药。
  • erm(41) T28多态性及rrl A2059G突变影响克拉霉素敏感性,需结合菌种和基因型选药。

核心结论

  • 在台湾,阿米卡星、克拉霉素和替加环素对MMA和MAB erm(41) C28序列型分离株有较好活性。
  • 阿米卡星和替加环素(而非克拉霉素)对MBO和MAB erm(41) T28序列型分离株有较好活性。

研究设计与样本

  • 研究纳入67株来自皮肤软组织感染患者的MABC分离株。
  • 采用secA1、rpoB和hsp65部分基因测序将菌株分为MAB、MMA和MBO三个亚种。
  • 按CLSI推荐使用肉汤微量稀释法和Sensititre RAPMYCOI MIC板测定11种抗分枝杆菌药物的MIC。

主要发现

  • 67株中鉴定出28株MAB、38株MMA和1株MBO。
  • 多数MABC菌株对环丙沙星、多西环素、亚胺培南、利奈唑胺、米诺环素、莫西沙星和复方磺胺甲噁唑耐药。
  • 多数MABC菌株对头孢西丁中介或耐药。
  • 38株MMA中2株存在rrl A2059G点突变。

关键数值与推荐

  • 67株MABC中MAB 28株、MMA 38株、MBO 1株。
  • 38株MMA中2株存在rrl A2059G点突变。

临床怎么用

  • 对皮肤软组织感染的MABC,经验性治疗可优先考虑阿米卡星和替加环素,但需结合菌种鉴定和erm(41)基因型判断克拉霉素是否适用。
  • 对erm(41) T28型MAB或MBO感染,不宜依赖克拉霉素,应选用阿米卡星和替加环素等有活性的药物。

局限性

  • 研究为单中心回顾性分离株分析,样本量有限。
  • 作者指出需临床试验将药敏数据与临床结局相关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycobacterium abscessus complex (MABC) is the most common non-tuberculous mycobacterium that causes complicated skin and soft tissue infections (cSSTIs). The selection of antimycobacterial agents for successful treatment of such infections is a critical issue. OBJECTIVES: To investigate the antimicrobial susceptibility patterns of MABC isolates from skin and soft tissue to a variety of antimycobacterial agents. METHODS: Sixty-seven MABC isolates were collected and partial gene sequencing of secA1, rpoB and hsp65 was used to classify them into three subspecies: M. abscessus subsp. abscessus (MAB), M. abscessus subsp. massiliense (MMA) and M. abscessus subsp. bolletii (MBO). The MICs of 11 antimycobacterial agents for these 67 isolates were determined using a broth microdilution method and commercial Sensititre RAPMYCOI MIC plates, as recommended by CLSI. RESULTS: In total, 28 MAB, 38 MMA and 1 MBO were isolated from patients with cSSTIs at our hospital. Most MABC strains were resistant to ciprofloxacin, doxycycline, imipenem, linezolid, minocycline, moxifloxacin and trimethoprim/sulfamethoxazole. In addition, most MABC strains were intermediately susceptible or resistant to cefoxitin. Eighteen of the 28 MABs and 1 MBO isolate harboured the T28 polymorphism in the erm(41) gene. Two of the 38 MMA isolates had an rrl A2059G point mutation. Most of the MABC strains were susceptible to amikacin and tigecycline. CONCLUSIONS: In Taiwan, amikacin, clarithromycin and tigecycline have good activity against MMA and MAB erm(41) C28 sequevar isolates, whereas amikacin and tigecycline, rather than clarithromycin, have good activity against both MBO and MAB erm(41) T28 sequevar isolates. Clinical trials are warranted to correlate these data with clinical outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lee MC, Sun PL, Wu TL, et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. J Antimicrob Chemother. 2017. PMID: 29091186. doi:10.1093/jac/dkx212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。